MNG431
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.428
- KRAS_SIGNALING_DN+0.333
- PANCREAS_BETA_CELLS+0.333
- ANGIOGENESIS+0.232
- APICAL_SURFACE+0.203
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.202
- TNFA_SIGNALING_VIA_NFKB+0.162
- MYOGENESIS+0.136
- COAGULATION+0.131
- SPERMATOGENESIS+0.084
Top 10 suppressed
- PROTEIN_SECRETION-0.524
- MITOTIC_SPINDLE-0.517
- TGF_BETA_SIGNALING-0.375
- UV_RESPONSE_DN-0.375
- PI3K_AKT_MTOR_SIGNALING-0.357
- INTERFERON_ALPHA_RESPONSE-0.346
- G2M_CHECKPOINT-0.319
- WNT_BETA_CATENIN_SIGNALING-0.294
- HEDGEHOG_SIGNALING-0.293
- UNFOLDED_PROTEIN_RESPONSE-0.287
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-A4CL-01A-41R-A26W-07 | — | cohortSQ2 | 0.840 |
| 2 | MNG810 | — | — | 0.825 |
| 3 | TCGA-LL-A5YL-01A-12R-A29R-07 | — | B | 0.822 |
| 4 | MNG506 | — | — | 0.819 |
| 5 | TCGA-KQ-A41P-01A-12R-A33J-07 | — | — | 0.813 |
| 6 | MNG764 | — | — | 0.804 |
| 7 | SRR1411024 | GTEX | — | 0.803 |
| 8 | TCGA-XF-A8HF-01A-11R-A36F-07 | — | — | 0.801 |
| 9 | TCGA-S5-A6DX-01A-11R-A31N-07 | — | — | 0.797 |
| 10 | TCGA-49-4514-01A-21R-1858-07 | — | cohortA4 | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.428 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.333 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.333 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.232 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.203 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.202 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.162 | Inavolisib | — uncovered |
| MYOGENESIS | 0.136 | Inavolisib | — uncovered |
| COAGULATION | 0.131 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.084 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.074 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.065 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.042 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.032 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.005 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.004 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.001 | Inavolisib | — uncovered |